about
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeNew options with dabigatran etexilate in anticoagulant therapyClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes.Current treatment of acute lower extremity deep venous thrombosis.
P2860
description
im Juli 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2007
@uk
name
A Replacement for Warfarin
@en
A Replacement for Warfarin
@nl
type
label
A Replacement for Warfarin
@en
A Replacement for Warfarin
@nl
prefLabel
A Replacement for Warfarin
@en
A Replacement for Warfarin
@nl
P1433
P1476
A Replacement for Warfarin
@en
P2093
Jeffrey I. Weitz
P304
P356
10.1161/CIRCULATIONAHA.107.712349
P407
P577
2007-07-10T00:00:00Z